Impact of TAS‑102 dose reduction on severe neutropenia and survival outcomes in patients with metastatic colorectal cancer and prior chemotherapy‑induced neutropenia
Authors:
Open Access
- 7 November 2025
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 24 (1) , 1-7
Abstract
The present study aimed to evaluate the impact of initial dose reduction of trifluridine/tipiracil (TAS‑102) monotherapy on the incidence of severe neutropenia and overall survival (OS) in individuals with metastatic colorectal cancer, considering prior chemotherapy‑induced severe neutropenia. Participants were classified into the following three groups: A group, individuals who did not experience severe neutropenia during previous chemotherapy and did not undergo dose reduction (n=61); B1 group, those who experienced severe neutropenia during previous chemotherapy and received an initial dose reduction of TAS‑102 (n=28); and B2 group, those who experienced severe neutropenia but did not receive a dose reduction (n=88). Neutropenia severity, progression‑free survival (PFS) and OS were compared among the groups. Notably, there was no significant difference in the incidence of grade 3 or higher neutropenia among the three groups during TAS‑102 administration (P=0.958). The median OS times in the A group (n=61), B1 group (n=28) and B2 group (n=88) were 273 days (95% CI, 199‑299), 285 days (95% CI, 202‑NA) and 233 days (95% CI, 182‑272), respectively (log‑rank test, P=0.165). The median PFS times among the three groups were 133.0 days (95% CI, 98‑153), 94.5 days (95% CI, 77‑133) and 93.5 days (95% CI, 83‑100), respectively (log‑rank test, P=0.053). In conclusion, a proactive dose reduction at TAS‑102 treatment initiation based on pre‑existing severe neutropenia should be carefully considered, as it may not be necessary.Keywords
This publication has 29 references indexed in Scilit:
- Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancerScientific Reports, 2024
- Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?Clinical Oncology, 2021
- Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective studyCancer Chemotherapy and Pharmacology, 2020
- Reply to the letter to the editor ‘Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil’ by Colloca et al.Annals of Oncology, 2020
- TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trialThe Lancet Oncology, 2020
- Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trialsAnnals of Oncology, 2020
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOXEuropean Journal of Cancer, 2009
- Getting the right dose in cancer chemotherapy – time to stop using surface area?British Journal of Cancer, 2002
- How to calculate the dose of chemotherapyBritish Journal of Cancer, 2002